thymosin beta-4 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-01-02. Where a claim depends on a specific study, the study is described rather than over-claimed.
Once in solution, short peptides are generally less stable than the dry powder, and repeated freeze-thaw cycles are a common cause of loss. Laboratory guidance usually calls for aliquoting on first dissolution and storing aliquots at -20 °C or below, away from light. Adsorption to plastic and glass surfaces can lower measured concentration, particularly at low concentrations, so container material and buffer choice can affect results. Visible cloudiness, colour change or unexpected precipitate is a signal to re-check the material.
Purity is normally assessed by reversed-phase HPLC, with the main peak reported as a percentage of total peak area, while identity is confirmed by mass spectrometry. Electrospray and MALDI-TOF instruments are both used, and the observed mass is compared with the value calculated from the stated sequence. Ion-exchange or size-exclusion methods appear where aggregation or charge variants are of interest. Water content, counter-ion content and residual trifluoroacetate from purification are separate variables that can shift the measured mass and should be weighed when reading a certificate of analysis.
Research peptides are typically supplied as a white to off-white lyophilised powder in a sealed vial. The dry solid is more stable than a solution and is normally kept refrigerated or frozen until use. Dissolution is usually done in water, phosphate-buffered saline or a similar aqueous medium, depending on the assay. Because the material is hygroscopic and easily contaminated, opening vials in a low-humidity environment and recording the lot number before use are standard laboratory practices.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
| Property | Value | Notes |
|---|---|---|
| Typical form | Lyophilised powder | Reconstituted before use |
| Storage temperature, dry | -20 °C or below | Desiccated, protected from light |
| Purity determination | Reversed-phase HPLC | Reported as percentage of total peak area |
| Identity confirmation | Mass spectrometry | ESI or MALDI-TOF versus calculated mass |
| Common synonyms | Tβ4 fragment; thymosin beta-4 fragment | Naming varies between suppliers |
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
==== Revision surgery ==== After a breast-augmentation surgery, the patient faces the possibility of a medical complication arising from the physical and the physiological changes undergone by the cut tissues of the body (chest muscles, underlying soft tissues, skin-envelope of the breast hemisphere), thus the surgical wounds are greatly susceptible to external contamination, bacterial infection, and physical damage — especially in the cases of women who underwent a breast-enlargement surgery whilst also undergoing scheduled radiation therapy. A woman with breast cancer usually undergoes a revision surgery to re-establish the symmetry between the nipple-areola complex of each breast and so recreate the natural appearance of her bust (size, form, feel). The rate of revision surgeries was three-point-zero per cent (3.0%) at the seven-year mark, compared to the re-operation rate of twenty per cent (20%) at the three-year mark. The therapeutic indications for a re-operation (revision surgery) of the augmented breast are: medical complications, capsular contracture, shell-rupture of the medical device, leakage of the silicone-gel filler material, and the rupture-and-deflation of the prosthetic breast.
haemoglobin F (foetal haemoglobin, HbF), consisting of two alpha (α-globin) and two gamma (γ-globin) chains. This dominates during foetal development and until about 6 weeks of age. Afterwards, haemoglobin A remains dominant throughout life. haemoglobin A (adult haemoglobin, HbA), which consists of two alpha and two beta (β-globin) chains. This is the most common human haemoglobin tetramer, accounting for over 97% of the total red blood cell haemoglobin in normal adults. Haemoglobin B2 (HbA2) is a second form of adult haemoglobin and is composed of two alpha and two delta (δ-globin) chains. This haemoglobin typically comprises 1–3% of haemoglobin in adults. β-globin is encoded by the HBB gene on human chromosome 11; mutations in this gene produce variants of the protein which are implicated with abnormal hemoglobins. The mutation that causes sickle cell disease results in an abnormal haemoglobin known as haemoglobin S (HbS), which replaces HbA in adults. The human genome contains a pair of genes for β-globin; in people with sickle cell disease, both genes are affected, and the erythropoietic cells in the bone marrow will only create HbS. In people with sickle cell trait, only one gene is abnormal; erythropoiesis generates a mixture of normal HbA and sickle HbS. The person has very few, if any, symptoms of sickle cell disease but carries the gene and can pass it on to their children. Sickle cell disease has an autosomal recessive pattern of inheritance.
=== Leucine === The leucine synthesis pathway diverges from the valine pathway beginning with α-ketoisovalerate. α-Isopropylmalate synthase catalyzes this condensation with acetyl CoA to produce α-isopropylmalate. An isomerase converts α-isopropylmalate to β-isopropylmalate. The third step is the NAD+-dependent oxidation of β-isopropylmalate catalyzed by a dehydrogenase. The final step is the transamination of the α-ketoisocaproate by the action of a glutamate-leucine transaminase. Leucine, like valine, regulates the first step of its pathway by inhibiting the action of the α-Isopropylmalate synthase. Because leucine is synthesized by a diversion from the valine synthetic pathway, the feedback inhibition of valine on its pathway also can inhibit the synthesis of leucine.
Sources: en.wikipedia.org
== Technology == CIM monoliths are made of porous methacrylate polymers composed of interconnected channels that range in size from 1-6 μm. It is these channels that account for the media separation power and flow characteristics and ability to purify large biomolecules, such as large proteins, immunoglobulins, plasmid DNA and viruses with their activity intact. Components to be separated are conveyed to the active groups located on the surface of the channels by bulk flow of the mobile phase. Since the channels are interconnected, there is no diffusion, no dead end pores, no void volume and no stagnant zones to slow down the transport between the stationary and mobile phase. Consequently, monolithic columns have flow independent resolution and binding capacity. They exhibit low back pressure, even at very high flow rates. In this way, the purification time can be significantly decreased, resulting in a pronounced reduction of the purification process costs.
Racemic crystallography is a technique used in structural biology where crystals of a protein molecule are developed from an equimolar mixture of an L-protein molecule of natural chirality and its D-protein mirror image. L-protein molecules consist of 'left-handed' L-amino acids and the achiral amino acid glycine, whereas the mirror image D-protein molecules consist of 'right-handed' D-amino acids and glycine. Typically, both the L-protein and the D-protein are prepared by total chemical synthesis.
The xanthophyll cycle involves the enzymatic removal of epoxy groups from xanthophylls (e.g. violaxanthin, antheraxanthin, diadinoxanthin) to create so-called de-epoxidised xanthophylls (e.g. diatoxanthin, zeaxanthin). These enzymatic cycles were found to play a key role in stimulating energy dissipation within light-harvesting antenna proteins by non-photochemical quenching- a mechanism to reduce the amount of energy that reaches the photosynthetic reaction centers. Non-photochemical quenching is one of the main ways of protecting against photoinhibition. In higher plants, there are three carotenoid pigments that are active in the xanthophyll cycle: violaxanthin, antheraxanthin, and zeaxanthin. During light stress, violaxanthin is converted, i.e. reduced, to zeaxanthin via the intermediate antheraxanthin, which plays a direct photoprotective role acting as a lipid-protective anti-oxidant and by stimulating non-photochemical quenching within light-harvesting proteins. This conversion of violaxanthin to zeaxanthin is done by the enzyme violaxanthin de-epoxidase (EC 1.23.5.1), while the reverse reaction, i.e. oxidation, is performed by zeaxanthin epoxidase (EC 1.14.15.21). In diatoms and dinoflagellates, the xanthophyll cycle consists of the pigment diadinoxanthin, which is transformed into diatoxanthin (diatoms) or dinoxanthin (dinoflagellates) under high-light conditions. Wright et al.
Sources: en.wikipedia.org
For example, the α decay of 239Pu to 235U can be used as an example of this procedure. with the assumption of a perfect purification time T0 then there will be a linear relationship between the in-growth of 235U and time elapsed since purification. There are, however, various instances where the correlation is not as clear. This strategy may not apply when the parent-daughter pair achieve secular equilibrium very rapidly or when the half-life of the daughter nuclide is significantly shorter than the time that has elapsed since purification of the nuclear material, e.g. 237Np/233Pa. Another possible complication is if in environmental samples, non-equivalent metal/ion transport for parents and daughter species may complicate or invalidate the use of chronometric measurements. Special age-dating relationships exist, including the commonly employed 234U/230Th and 241Pu/241Am chronometers. In special circumstances, parent-granddaughter relationships can be used to elucidate the age of nuclear materials when the material is intentionally made to look older through the addition of daughter nuclides. Chronometry is based on the concept that the composition of the nuclear material changes as samples are prepared and analyzed. This barrier can be substantial for species that decay quickly or whose daughter products put forth spectral interferences. The decay of 233U, for example, has a t1/2~1.6×105years which is rapid in comparison to many species and yield 229Th, which emits an α particle that is isoenergetic, having the same energy, as the parent.
Microbial growth and proliferation can be inhibited by a technique called biopreservation. Biopreservation is achieved by adding antimicrobials or by increasing the acidity of the fish muscle. Most bacteria stop multiplying when the pH is less than 4.5. Acidity is increased by fermentation, marination or by directly adding acids (acetic, citric, lactic) to fish products. Lactic acid bacteria produce the antimicrobial nisin which further enhances preservation. Other preservatives include nitrites, sulfites, sorbates, benzoates and essential oils.
=== Marinating swordfish === A traditional method marinating swordfish is to soak the swordfish into sake kasu. Normally, marinating food ingredients in sake kasu can increase the amount of inosine-monophosphate thus increasing the umami flavor of the dish. Soaking swordfish in sake kasu will decrease the amount of inosine-monophosphate in the swordfish and increase the level of inosine and the amount of inosine-monophosphate in the sake kasu marinade.
Sources: en.wikipedia.org
Sealed, desiccated and protected from light, at -20 °C or lower for long-term storage. Short-term storage at refrigerator temperature is common in working laboratories.
Synthesis routes, purification steps and the analytical method used all affect the reported figure. A purity number is only comparable when the chromatographic conditions and detection wavelength are stated.
It reports what the supplier measured on a sample, which is useful but not absolute. Independent mass confirmation on the received lot is the more reliable check.
No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.